Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735, A Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors; 22% Placebo-Adjusted Weight Loss Reported At Week 33 Following Weekly Dosing Of VK2735At 17.5 MG; No Plateau Observed
Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to TreatmentUp to 97% of Weight Loss Maintained Following Transition to Every
Viking tested a new weight loss drug called VK2735 on people. The drug kept working well, and people could take it less often. This matters because easier dosing means more people might actually stick with treatment. When you see this stock, watch if the company moves forward to the next testing stage.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.